Acute Lymphoblastic Leukemia in Children: Better Transplant Outcomes After Total Body Irradiation-based Conditioning

Overview

Journal In Vivo

Specialty Oncology

Date 2021 Oct 26

PMID 34697163

Citations 4

Authors

Jan Styczynski

Robert Debski

Krzysztof Czyzewski

Katarzyna Gagola

Ewa Marquardt

Krzysztof Roszkowski

Janusz Winiecki

Ninela Irga-Jaworska

Marcin Hennig

Katarzyna Muszynska-Roslan

Marcin Plonowski

Tomasz Ociepa

Monika Lecka

Joanna Konieczek

Przemyslaw Galazka

Monika Pogorzala

Monika Richert-Przygonska

Mariusz Wysocki

Affiliations

Soon will be listed here.

Abstract

Background/aim: Comparison of transplant outcomes in long-term follow-up of children after total body irradiation (TBI)- or chemotherapy-based conditioning allogeneic hematopoietic cell transplantation (allo-HCT).

Patients And Methods: Patients undergoing allo-HCT for Acute lymphoblastic leukemia (ALL) conditioned either with TBI (n=55) or chemotherapy (n=84) were compared. The following transplant outcomes were analyzed: overall survival (OS), event-free survival (EFS), relapse incidence (RI), and graft-versus-host-disease (GVHD)-free-relapse-free survival (GRFS).

Results: All analyzed long-term transplant outcomes were significantly better for patients conditioned with TBI at 2 years after transplant. OS at 2 years was 84% after TBI and 60.5% after chemotherapy-conditioning (p=0.005). Risk factor analysis showed that two factors, TBI-based conditioning and transplant in first remission of ALL, significantly improved OS, EFS, GRFS, and decreased RI.

Conclusion: TBI-based conditioning before allogeneic HCT in children with acute lymphoblastic leukemia provides significantly better transplant outcomes, when compared to chemotherapy-based conditioning.

Citing Articles

Charting Health Challenges for Digital Preventive Interventions Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia: National Long-Term Follow-Up Survey of Self-Rated Health Outcomes.

Nygren J, Aili K, Arvidsson S, Olsson M, Jarfelt M JMIR Form Res. 2024; 8:e54819.

PMID: 39133918 PMC: 11347897. DOI: 10.2196/54819.

Influence of Minimal Residual Disease at Day 15 of Induction Therapy on Survival of Children with Acute Lymphoblastic Leukemia.

Samardzic-Predojevic J, durdevic-Banjac B, Malcic-Zanic D Acta Med Acad. 2024; 52(3):153-160.

PMID: 38407081 PMC: 10945324. DOI: 10.5644/ama2006-124.427.

Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma.

Li Z, Zhang B, Fan X, Gui R, Yu F, Wang J Front Oncol. 2023; 13:1193237.

PMID: 37546390 PMC: 10399448. DOI: 10.3389/fonc.2023.1193237.

Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia.

Malczewska M, Kosmider K, Bednarz K, Ostapinska K, Lejman M, Zawitkowska J Cancers (Basel). 2022; 14(8).

PMID: 35454927 PMC: 9032060. DOI: 10.3390/cancers14082021.

References

Duarte R, Labopin M, Bader P, Basak G, Bonini C, Chabannon C . Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019; 54(10):1525-1552. DOI: 10.1038/s41409-019-0516-2. View

Yalcin K, Pehlivan B, Celen S, Bas E, Kabakci C, Pashayev D . Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL. J Pediatr Hematol Oncol. 2021; 43(7):266-270. DOI: 10.1097/MPH.0000000000002055. View

Zawitkowska J, Lejman M, Zaucha-Prazmo A, Drabko K, Plonowski M, Bulsa J . Grade 3 and 4 Toxicity Profiles During Therapy of Childhood Acute Lymphoblastic Leukemia. In Vivo. 2019; 33(4):1333-1339. PMC: 6689363. DOI: 10.21873/invivo.11608. View

Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz M, Campbell M . Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood. 2021; 139(12):1785-1793. PMC: 8952186. DOI: 10.1182/blood.2021012328. View

Peters C, Dalle J, Locatelli F, Poetschger U, Sedlacek P, Buechner J . Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol. 2020; 39(4):295-307. PMC: 8078415. DOI: 10.1200/JCO.20.02529. View

Inaba H, Pui C . Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. J Clin Med. 2021; 10(9). PMC: 8124693. DOI: 10.3390/jcm10091926. View

Kebriaei P, Anasetti C, Zhang M, Wang H, Aldoss I, de Lima M . Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2017; 24(4):726-733. PMC: 5902420. DOI: 10.1016/j.bbmt.2017.11.025. View

Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W . Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015; 33(11):1265-74. DOI: 10.1200/JCO.2014.58.9747. View

Demidowicz E, Pogorzala M, Lecka M, Zolnowska H, Marjanska A, Kubicka M . Outcome of Pediatric Acute Lymphoblastic Leukemia: Sixty Years of Progress. Anticancer Res. 2019; 39(9):5203-5207. DOI: 10.21873/anticanres.13717. View

10.

Gupta T, Kannan S, Dantkale V, Laskar S . Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2011; 4(1):17-29. DOI: 10.5144/1658-3876.2011.17. View

11.

Hamidieh A, Monzavi S, Kaboutari M, Behfar M, Esfandbod M . Outcome Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia Treated with Total Body Irradiation-Free Allogeneic Hematopoietic Stem Cell Transplantation: Comparison of Patients with and Without Central Nervous System Involvement. Biol Blood Marrow Transplant. 2017; 23(12):2110-2117. DOI: 10.1016/j.bbmt.2017.08.036. View

12.

Boztug H, Zecca M, Sykora K, Veys P, Lankester A, Slatter M . Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Ann Hematol. 2014; 94(2):297-306. DOI: 10.1007/s00277-014-2196-8. View

13.

Holtan S, DeFor T, Lazaryan A, Bejanyan N, Arora M, Brunstein C . Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015; 125(8):1333-8. PMC: 4335084. DOI: 10.1182/blood-2014-10-609032. View

14.

Czyzewski K, Debski R, Bartoszewicz N, Demidowicz E, Richert-Przygonska M, Lecka M . Impact of Palifermin on Transplant Outcomes in Children and Adolescents Undergoing Allogeneic Hematopoietic Cell Transplantation. Anticancer Res. 2020; 40(11):6531-6537. DOI: 10.21873/anticanres.14677. View

15.

Kato M, Takahashi Y, Tomizawa D, Okamoto Y, Inagaki J, Koh K . Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia. Biol Blood Marrow Transplant. 2013; 19(12):1690-4. DOI: 10.1016/j.bbmt.2013.09.012. View

16.

Lejman M, Zawitkowska J, Zaucha-Prazmo A, Cienkusz M, Mroczkowska A, Kowalczyk J . Influence of Mixed Chimerism on Outcome in Children With Anaemia After Haematopoietic Stem Cell Transplantation. In Vivo. 2019; 33(6):2051-2057. PMC: 6899150. DOI: 10.21873/invivo.11703. View